Esophageal Squamous Cell Carcinoma Clinical Trials in Hangzhou, Zhejiang
5 recruitingHangzhou, Zhejiang, China
Showing 1–5 of 5 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC230 enrolled57 locationsNCT05319730
Recruiting
Phase 2
Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）
Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital92 enrolled1 locationNCT06509568
Recruiting
Phase 2
Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital37 enrolled1 locationNCT06422858
Recruiting
Phase 2
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
Esophageal Squamous Cell Carcinoma
Shanghai Zhongshan Hospital100 enrolled5 locationsNCT06637163
Recruiting
Phase 2
A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital31 enrolled1 locationNCT06190639